Anti-epileptic drugs inhibit viability of synoviocytes in vitro

Area of Science:

• Rheumatology
• Pharmacology
• Cell Biology

Background:

• Synovial fibroblast hyperplasia is a key factor in rheumatoid arthritis (RA) joint destruction.
• Previously, anti-rheumatic drugs were shown to inhibit synoviocyte proliferation in vitro.
• The therapeutic potential of anti-epileptic drugs (AEDs) in RA remains largely unexplored.

Purpose of the Study:

• To investigate the in vitro effects of AEDs on the viability and proliferation of synovial fibroblasts.
• To determine the efficacy of specific AEDs in inhibiting rheumatoid arthritis synovial cell growth.

Main Methods:

• Experiments utilized human rheumatoid arthritis (RA) synoviocytes and the HIG-82 rabbit synoviocyte cell line.
• Cell proliferation was assessed using the BrdU assay, and cell viability was measured by the MTT assay.
• The IC50 values, representing the drug concentration for 50% inhibition, were calculated for each tested AED.

Main Results:

• Carbamazepine demonstrated significant inhibition of human fibroblast proliferation (IC50: 86 µM) and HIG-82 cell viability (IC50: 82 µM).
• Other AEDs, including diphenylhydantoin, valproate, and phenobarbital, also inhibited HIG-82 cell viability with varying IC50 values (110 µM, 500 µM, and 1031 µM, respectively).

Conclusions:

• The findings suggest that certain AEDs possess anti-proliferative properties against rheumatoid arthritis synovial fibroblasts.
• AEDs may represent a novel class of disease-modifying agents for rheumatoid arthritis.
• Further research is warranted to explore the clinical application of AEDs in RA treatment.